Clemastine
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Clemastine: H1 antihistamine → nasal cavity disease
One-Sentence Summary
Clemastine is a first-generation H1 antihistamine with anticholinergic activity, marketed in India as single-ingredient syrups and tablets. The TxGNN model predicts it may be useful for nasal cavity disease, but the prediction currently has no clinical trials and no publications behind it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | nasal cavity disease |
| TxGNN Prediction Score | 0.9987 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (3 of 3) – CDSCO approval status is not included in this data |
| Number of Listed Products | 3 (valid: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Clemastine belongs to the first-generation H1 antihistamine class. These drugs block histamine H1 receptors and also have anticholinergic effects that can reduce nasal secretions.
“Nasal cavity disease” is a very broad term. The high score most likely reflects its overlap with common allergic and vasomotor nasal conditions rather than a distinct new repurposing signal. A plausible mechanistic link is H1 blockade combined with anticholinergic reduction of rhinorrhoea. No specific evidence was supplied to test this link, so the prediction rests on the model score alone.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 221649 | Taregyl 0.5mg Syrup | Bottle of 30 ml syrup | Not recorded |
| 220627 | Tavegyl Children Syrup | Bottle of 60 ml syrup | Not recorded |
| 219496 | Taregyl 1mg Tablet | Strip of 10 tablets | Not recorded |
All three authorizations are single-ingredient products from Novartis India Ltd and are currently valid.
Safety Considerations
- Contraindication-related conditions (from drug–disease relation data, not label text): hypertension, peptic ulcer disease, benign prostatic hyperplasia, ocular hypertension, angle-closure glaucoma, hyperthyroidism (including Graves disease and thyrotoxicosis), and bladder neck obstruction. These fit the drug’s anticholinergic and sedating profile, but they should be checked against the official package insert.
- Drug Interactions: 297 interactions were found. The main ones listed are:
- Major: potassium citrate and potassium chloride.
- Moderate: other anticholinergics (atropine, hyoscyamine, scopolamine, glycopyrronium, dicyclomine, propantheline) and opioids or CNS-active agents (morphine, loperamide, opium, dronabinol, nabilone).
- Moderate: metoclopramide and eluxadoline.
Package insert warnings and contraindications were not available, so please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or publications. The topic is also broad and overlaps with conditions clemastine is already used for, so it is not a distinct repurposing opportunity.
To proceed, the following is needed:
- A narrower, clinically meaningful definition of the target condition (for example, a specific type of rhinitis or nasal disorder).
- Published or registered studies of clemastine in that condition.
- Package insert warnings and contraindications from the Indian labels.
- Mechanism-of-action data for clemastine.
- A safety review for patients with the conditions listed above, and for use alongside other anticholinergic or CNS-active drugs.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.